Endocrinol Metab.  2020 Mar;35(1):194-195. 10.3803/EnM.2020.35.1.194.

Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

• Jang HN
• Jung HS

• KMID: 2471737
• DOI: http://doi.org/10.3803/EnM.2020.35.1.194

Abstract

No abstract available.

MeSH Terms

Adult*
Humans
Insulin*
Insulin

Reference

1. Jang HN, Yang YS, Lee SO, Oh TJ, Koo BK, Jung HS. Favorable glycemic control with once-daily insulin degludec/insulin aspart after changing from basal insulin in adults with type 2 diabetes. Endocrinol Metab (Seoul). 2019; 34:382–389. PMID: 31884738.

2. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015; 4:212283. PMID: 26213556.

3. Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, et al. Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016; 39:2026–2035. PMID: 27527848.

4. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020; 43(Suppl 1):S98–S110. PMID: 31862752.